Browsing Tag
ARVO
2 posts
Viatris and the presbyopia drug race: What ASCRS 2026 data means for the MR-141 FDA decision in October
Viatris presents full VEGA-3 Phase 3 data for MR-141 presbyopia drop at ASCRS 2026. FDA PDUFA date is October 17, 2026. Market context, competitive landscape, and investor outlook.
Why VG801 could reshape endpoint strategy in inherited retinal disease development
VG801 shows early vision gains in Stargardt disease. Discover how VeonGen Therapeutics is redefining endpoints and regulatory strategy.